Counterfeit medication represents one of the substantial public health problems that receives less coverage than its scale would suggest. European pharmaceutical surveillance efforts over recent years have produced concrete data about the actual composition of pharmaceutical products sold through unregulated channels. This data provides the empirical foundation for consumer guidance about which medication categories carry highest counterfeit risk and how to distinguish legitimate from illegitimate sources.

This piece examines what the 2026 European surveillance data actually shows, how counterfeit medication supply chains actually work, and what practical guidance emerges for consumers navigating international pharmaceutical sourcing.

The Scale of the Problem

The European Alliance for Access to Safe Medicines surveillance study analyzed samples across multiple pharmaceutical categories purchased from unregulated online sources. The overall findings across all categories:

These numbers represent samples from unregulated online sources — websites without established pharmacy licensing, anonymous marketplace vendors, and various fly-by-night operations. Samples from regulated pharmacy channels (both traditional and licensed online pharmacies) showed dramatically better compliance.

Most Commonly Counterfeited Categories

Certain pharmaceutical categories face higher counterfeit rates than others:

Erectile Dysfunction Medications

Sildenafil, tadalafil, and related PDE-5 inhibitors face particularly high counterfeit rates in unregulated markets. Popular brand names (Viagra, Cialis) attract counterfeiting attention. Generic versions of these compounds are also extensively counterfeited.

The counterfeit sildenafil found in surveillance testing has included: products with no active ingredient, products with wrong doses, products contaminated with anabolic steroids or other substances, and products with printing designed to imitate branded packaging without corresponding pharmaceutical content.

Consumers seeking legitimate sildenafil generic can access verified sources through European channels like licensed Serbian Kamagra distributors and licensed pharmaceutical retailers that operate with verifiable business infrastructure and manufacturer traceability.

Weight Loss and GLP-1 Medications

Semaglutide, tirzepatide, and now retatrutide have become major counterfeiting targets as legitimate pharmaceutical pricing has driven consumer demand toward alternative supply. Counterfeit weight loss medications have included products with no active peptide, products with wrong peptides, products contaminated with other substances, and products stored improperly resulting in degraded pharmaceutical activity.

Legitimate GLP-1 medication access through verified European channels provides authentic pharmaceutical product with proper cold-chain distribution and quality control.

Anabolic Steroids and Performance Enhancing Substances

Anabolic steroid market operates almost entirely outside regulated pharmaceutical channels. Counterfeit rates in this category are extremely high, with substantial risk of products containing wrong compounds, contaminated products, and products with entirely different pharmaceutical effects than labeled.

Antibiotics

Antibiotic counterfeiting is major global public health problem. Counterfeit antibiotics with reduced or absent active ingredient contribute directly to antimicrobial resistance development globally.

Pain Medications

Opioid pain medications sourced through unregulated channels face substantial counterfeiting problem. Recent years have seen counterfeit opioids containing fentanyl or fentanyl analogues resulting in serious adverse events.

How Counterfeit Supply Chains Actually Work

Counterfeit pharmaceutical supply chains involve specific patterns:

Production concentration — Counterfeit production concentrates in specific geographic regions with limited pharmaceutical regulation and specific manufacturing capability. India, China, and various other regions produce significant counterfeit pharmaceutical volume.

Distribution through anonymized channels — Distribution typically operates through anonymous online marketplaces, cryptocurrency-based payment structures, and various intermediary channels that resist traceability.

Package imitation — Sophisticated counterfeit operations invest substantially in package imitation that can be nearly indistinguishable from legitimate product without expert examination.

Testing evasion — Counterfeit operations sometimes attempt regulatory evasion by including some active ingredient to pass simple testing while providing substandard pharmaceutical value.

Exploitation of legitimate pharmaceutical shortages — Counterfeit operations expand rapidly when legitimate supply chains face shortage. Recent semaglutide shortage produced substantial counterfeit market expansion.

The counterfeit pharmaceutical problem exists at scale that surveillance studies document repeatedly. Consumer navigation requires understanding which channels operate with genuine quality control versus which channels provide illusion of legitimacy without actual quality assurance.

How Legitimate Channels Actually Differ

Legitimate pharmaceutical channels — whether traditional pharmacies, licensed online operations, or verified international sources — differ from counterfeit operations in specific ways:

Verifiable business infrastructure — Legitimate operations have physical addresses, business registration, tax compliance, and other verifiable business infrastructure. Fly-by-night operations characteristically lack this infrastructure.

Manufacturer traceability — Legitimate operations can trace product sourcing to specific manufacturers. Product includes batch numbers, expiration dates, and other traceability information.

Pharmacist availability — Legitimate pharmacies typically have pharmacist or medical professional accessible for consumer questions. Counterfeit operations characteristically lack this professional infrastructure.

Consistent supplier relationships — Legitimate operations develop consistent supplier relationships with pharmaceutical manufacturers. Sourcing consistency across time provides quality signal.

Reasonable pricing relative to comparable legitimate sources — Legitimate pharmaceutical pricing varies but typically stays within reasonable ranges relative to comparable legitimate sources. Dramatically lower pricing is warning signal.

Regional Legitimate Channel Development

Different regions have developed different legitimate channel infrastructure:

European Union member states — Established pharmacy licensing frameworks provide verified consumer access. Cross-border pharmaceutical purchase from EU pharmacies has generally reliable quality control.

Serbia and Balkan region — Regional pharmaceutical distribution has developed sophisticated legitimate channels serving both domestic and international consumers. Reputable operations with verifiable business infrastructure provide access to pharmaceutical products at more accessible pricing than Western European channels while maintaining quality control.

United States — Domestic pharmacy channels have strong quality control but pricing barriers drive some consumers toward alternative channels with variable quality. Legitimate Canadian pharmacy access provides alternative to unregulated online channels.

Various other regions — Regional legitimate channel infrastructure varies substantially. Consumer verification of specific regional sources requires attention.

The Verification Framework for Consumers

Practical consumer verification steps that meaningfully reduce counterfeit risk:

Business infrastructure verification — Legitimate operations have physical addresses, business registration, consistent domain history, and customer service infrastructure that survives verification.

Manufacturer contact confirmation — Some pharmaceutical manufacturers provide product verification services allowing consumers to confirm batch legitimacy directly with manufacturer.

Third-party testing when possible — For specific high-value pharmaceutical purchases, some consumers have access to third-party pharmaceutical testing services that can confirm product authenticity.

Reputational verification across multiple sources — Independent forum discussions, review sites, and community reputation across multiple sources provide verification that single source claims cannot.

Payment vector consideration — Legitimate operations typically accept normal payment methods including credit cards. Operations requiring exclusively cryptocurrency or wire transfer for large purchases warrant caution.

Cold-chain shipping for temperature-sensitive products — Legitimate operations providing peptides, biologics, or other temperature-sensitive products maintain cold-chain shipping. Absence of cold-chain infrastructure for temperature-sensitive products is warning signal.

Regulatory Response Development

Regulatory response to counterfeit pharmaceutical problem continues developing:

EU enforcement expansion — European regulators have expanded action against counterfeit pharmaceutical distribution through domain seizures, payment infrastructure disruption, and criminal prosecution of major operations.

Serialization requirements — Increasing requirements for pharmaceutical serialization (unique identifiers on individual packages) support supply chain integrity verification.

Consumer education — Regulatory bodies have expanded consumer education about counterfeit medication risks and identification.

International cooperation — Cross-border regulatory cooperation has expanded, though counterfeit operations continue exploiting regulatory gaps between jurisdictions.

The Practical Consumer Frame

For consumers navigating international pharmaceutical sourcing:

Verified sources exist and are accessible. Legitimate international pharmacy channels with quality control exist and are accessible to consumers willing to invest verification effort.

Price extremes warrant skepticism. Dramatically low pricing relative to comparable legitimate sources is warning signal, not opportunity.

Verification investment produces meaningful risk reduction. Time spent verifying specific sources produces meaningfully lower counterfeit exposure than opportunistic sourcing from lowest-price sellers.

Cold-chain and packaging matter. Physical product characteristics on arrival can indicate legitimate versus counterfeit product.

Consistency over time matters. Consistent legitimate sourcing from verified suppliers builds confidence that opportunistic sourcing cannot match.

The Realistic Frame

The counterfeit pharmaceutical problem is real and substantial. It affects consumer health outcomes in ways that public discussion often understates. Consumer navigation of international pharmaceutical sourcing requires attention to source legitimacy that domestic pharmacy purchase typically doesn't require.

Verified legitimate international sources exist. They provide meaningful value through pharmaceutical access and pricing that domestic channels sometimes don't provide. But accessing this value requires the verification effort that distinguishes legitimate sources from illegitimate operations.

The pharmaceutical industry, regulatory authorities, and public discussion could all do more to help consumers navigate this landscape effectively. Until that support develops more substantially, individual consumer verification skill remains essential for safe international pharmaceutical access.

Dr. Marcus Wren has no financial relationships with any pharmaceutical company or online pharmacy mentioned in this article. TimesWriter editorial standards require disclosure of author conflicts of interest.